Skip Navigation
 
 
 
Print This Page

Gastroenterology

1. Aprepitant for the Relief of Nausea in Patients with Chronic Nausea and Vomiting of Presumed Gastric Origin (APRON)

We are seeking adults ages 18 and older who have experienced symptoms of chronic nausea and vomiting related to gastroparesis for at least 6 months. This research study is being done to find out whether taking the drug aprepitant is better than a placebo in improving the symptoms of chronic nausea and vomiting. We also hope to find out how aprepitant affects other symptoms life fullness, hunger, bloating, abdominal pain, and if there are any significant side effects. Aprepitant is approved by the Food and Drug Administration (FDA) for the treatment of nausea and vomiting after chemotherapy or surgery. It is not approved for use in gastroparesis, although it used by some doctors to reduce nausea and vomiting in similar patients. The FDA is allowing the use of aprepitant in this research study. Study-related treatments and procedures will be provided at no cost to you.

For more information about this study, please contact the study coordinator at 410-550-6871.

PI: Pankaj Jay Pasricha, M.D.
NA_00079335


2. Gastroparesis Registry 2 (GpR2): Continuation of the NIDDK Registry for the Characterization and Clinical Course of Gastroparesis Patients

The Gastroparesis Registry 2 is an observational study of patients with gastroparesis. This is the second registry study of gastroparesis started by the Gastroparesis Clinical Research Consortium funded by NIH. People with gastroparesis suffer from nausea, vomiting, stomach pain, feeling full after eating and/or losing weight. Why people develop gastroparesis is not known. People with diabetes, prior stomach surgery, or who have had certain viral infections seem to be at greater risk of developing this condition. The purpose of this study is to better understand gastroparesis and data collected may improve the understanding of the condition to enable better diagnosis and treatment.

We are seeking adults (18 and older) with symptoms of gastroparesis (nausea, vomiting, early satiety, fullness, abdominal pain). About 1000 people will take part in this study at 9 medical centers participating in this research study across the country. You will not receive drugs or medications as part of the Gastroparesis Registry 2. Study-related visits and procedures will be provided at no cost to you.

For more information about this study, please contact the study coordinator at 410-550-6871.

PI: Pankaj Jay Pasricha, M.D.
NA_00077378

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.